Shares of Procter & Gamble Health rallied over 18% to hit an intraday high of ₹6,700 on the National Stock Exchange (NSE) following the company's strong January-March quarter performance. According to reports from Business Standard, at around 01:45 PM, the stock was trading at ₹6,267, representing an 11% increase from the previous session's close of ₹5,652.5. The company's market capitalisation stood at ₹10,402 crore, with its 52-week high at ₹6,739 and 52-week low at ₹4,707.
P&G Health delivered impressive financial results for the March 2026 quarter, with net profit surging 56% year-on-year to ₹95 crore compared to ₹61 crore in the corresponding quarter of the previous fiscal. As reported by Business Standard, the company's revenue from operations increased 19% Y-o-Y to ₹370 crore in the January-March quarter, up from ₹311 crore in the year-ago period. The company's EBITDA jumped 67% to ₹135 crore from ₹81 crore in the previous year, with EBITDA margin expanding significantly to 36.57% from 26.02%.
The board of directors have recommended a final dividend of ₹45 per equity share for FY26, subject to shareholder approval at the upcoming annual general meeting. According to Business Standard, the total dividend payout for the fiscal year will be ₹205 per share, reflecting the company's strong cash generation capabilities and commitment to returning value to shareholders.
Milind Thatte, Managing Director at Procter & Gamble Health, highlighted the company's strong performance delivery. As reported by Business Standard, Thatte stated the company delivered consistent top-line and bottom-line growth while continuing to invest across the value chain to address evolving consumer and healthcare professional needs. He emphasized the company's strategy centered on a focused portfolio of quality, trusted brands where performance drives brand choice, with focus on superiority, constructive disruption, productivity, and an agile organization.
